» Articles » PMID: 32397414

Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold

Overview
Journal Cells
Publisher MDPI
Date 2020 May 14
PMID 32397414
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Chimeric antigen receptor (CAR)-T cells have demonstrated significant clinical potential; however, their strong antitumor activity may cause severe adverse effects. To ensure efficacy and safe CAR-T cell therapy, it is important to understand CAR's structure-activity relationship. To clarify the role of hinge and transmembrane domains in CAR and CAR-T cell function, we generated different chimeras and analyzed their expression levels and antigen-specific activity on CAR-T cells. First, we created a basic CAR with hinge, transmembrane, and signal transduction domains derived from CD3ζ, then we generated six CAR variants whose hinge or hinge/transmembrane domains originated from CD4, CD8α, and CD28. CAR expression level and stability on the T cell were greatly affected by transmembrane rather than hinge domain. Antigen-specific functions of most CAR-T cells depended on their CAR expression levels. However, CARs with a CD8α- or CD28-derived hinge domain showed significant differences in CAR-T cell function, despite their equal expression levels. These results suggest that CAR signaling intensity into T cells was affected not only by CAR expression level, but also by the hinge domain. Our discoveries indicate that the hinge domain regulates the CAR signaling threshold and the transmembrane domain regulates the amount of CAR signaling via control of CAR expression level.

Citing Articles

Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis.

Oh S, Khani-Habibabadi F, OConnor K, Payne A Sci Adv. 2025; 11(9):eadt0795.

PMID: 40020066 PMC: 11870065. DOI: 10.1126/sciadv.adt0795.


CAR-T Cell Manufacturing for Hematological and Solid Tumors: From the Preclinical to Clinical Point of View.

Capolla S, Rasool M, Toffoli G, Dal Bo M Cancer Med. 2025; 14(5):e70726.

PMID: 40013750 PMC: 11866474. DOI: 10.1002/cam4.70726.


From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy.

Pinto E, Lione L, Compagnone M, Paccagnella M, Salvatori E, Greco M J Transl Med. 2025; 23(1):10.

PMID: 39755643 PMC: 11700462. DOI: 10.1186/s12967-024-06052-3.


Application of novel CAR technologies to improve treatment of autoimmune disease.

Cheever A, Kang C, ONeill K, Weber K Front Immunol. 2024; 15:1465191.

PMID: 39445021 PMC: 11496059. DOI: 10.3389/fimmu.2024.1465191.


Universal protection of allogeneic T-cell therapies from natural killer cells via CD300a agonism.

Zhang S, Zhang S, Thomas F, Fang J, Austgen K, Cowan C Blood Adv. 2024; 9(2):254-264.

PMID: 39368806 PMC: 11782830. DOI: 10.1182/bloodadvances.2024013436.


References
1.
Ying Z, He T, Wang X, Zheng W, Lin N, Tu M . Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma. Mol Ther Oncolytics. 2019; 15:60-68. PMC: 6804784. DOI: 10.1016/j.omto.2019.08.002. View

2.
Restifo N, Dudley M, Rosenberg S . Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12(4):269-81. PMC: 6292222. DOI: 10.1038/nri3191. View

3.
Brudno J, Kochenderfer J . Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2017; 15(1):31-46. DOI: 10.1038/nrclinonc.2017.128. View

4.
Fujiwara K, Masutani M, Tachibana M, Okada N . Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties. Biochem Biophys Res Commun. 2020; 527(2):350-357. DOI: 10.1016/j.bbrc.2020.03.071. View

5.
Drent E, Poels R, Ruiter R, van de Donk N, Zweegman S, Yuan H . Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells. Clin Cancer Res. 2019; 25(13):4014-4025. PMC: 7477921. DOI: 10.1158/1078-0432.CCR-18-2559. View